Professor Mallika Imwong
Malariologist at Mahidol Department of Molecular Tropical Medicine and Genetics
- Honorary Visiting Research Fellow in Tropical Medicine
My research works have focused on three aspects:
- to understand how drug resistance emerges and spreads in malaria parasites in Asia and Africa
- to detect and characterise the true epidemiology of malaria in low transmissions setting
- to investigate the biology of relapse of benign malaria.
I am currently involved in surveillance studies describing the molecular epidemiology of drug resistance in different parts of the region including Thai-Burmese border, Eastern Thailand, Cambodia, Vietnam, Laos PDA, and Afghanistan. A key objective is to determine the genetic and mechanistic basis for increased resistance of P. falciparum to artemisinin. The development of an inexpensive and effective genetic tool is essential for public health monitoring for artemisinin resistance. My ongoing projects will use genotyping markers or phenotypic properties for the fitness cost alleviating genetic variants validated loci and conduct follow-up molecular epidemiological surveys to assess their prevalence throughout the GMS in the current state of transmission. Therefore, this will also allow us to assess the potential of the GMS to develop drug resistance phenotypes and to evaluate the potential that such phenotypes emerge in other parts of the malaria world (such as Africa), as control programs progress towards elimination.
Transnational spread of multidrug resistant PfPailin
Corrigendum to: A novel sensitive hexaplex high-resolution melt assay for identification of five human Plasmodium species plus internal control (Acta Tropica, volume 248, article number 107020).
Srisutham S. et al, (2023), Acta tropica
Limited Polymorphism in the Dihydrofolate Reductase (dhfr) and dihydropteroate synthetase genes (dhps) of Plasmodium knowlesi isolate from Thailand.
Sangsri R. et al, (2023), Acta tropica
Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin-piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia.
Rahmasari FV. et al, (2023), Malaria journal, 22
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Jittamala P. et al, (2023), The Journal of Infectious Diseases
In vitro activity of rhinacanthin analogues against drug resistant Plasmodium falciparum isolates from Northeast Thailand.
Chaorattanakawee S. et al, (2023), Malar J, 22